128,084 results match your criteria Alzheimer Disease

Artesunate restores mitochondrial fusion-fission dynamics and alleviates neuronal injury in Alzheimer's disease models.

J Neurochem 2022 May 21. Epub 2022 May 21.

Department of Neurology, Saarland University, Homburg, Germany.

Alzheimer's disease (AD) remains a leading cause of dementia and no therapy that reverses underlying neurodegeneration is available. Recent studies suggest the protective role of artemisinin, an antimalarial drug, in neurological disorders. In this study, we investigated the therapeutic potential of artesunate, a water-soluble derivative of artemisinin, on amyloid-beta (Aβ)-treated challenged microglial BV-2, neuronal N2a cells, and the amyloid precursor protein/presenilin (APP/PS1) mice model. Read More

View Article and Full-Text PDF

Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease.

Cell Mol Neurobiol 2022 May 21. Epub 2022 May 21.

Institute of Bioanalysis, Coburg University of Applied Sciences, Coburg, Germany.

Alzheimer disease (AD) is the most common progressive neurodegenerative disorder. AD causes enormous personal and economic burden to society as currently only limited palliative therapeutic options are available. The pathological hallmarks of the disease are extracellular plaques, composed of fibrillar amyloid-β (Aβ), and neurofibrillary tangles inside neurons, composed of Tau protein. Read More

View Article and Full-Text PDF

Epilepsy in neurodegenerative diseases.

Epileptic Disord 2022 Apr;24(2):249-273

Danish Epilepsy Centre, Dianalund, Denmark.

Although epilepsy as a comorbidity in neurodegenerative disorders is increasingly recognized, its incidence is still underestimated and the features of epilepsy in the different neurodegenerative conditions are still poorly defined. Improved health care, resulting in increased longevity, will unavoidably lead to an increment of epilepsy cases in the elderly. Thus, it is conceivable to expect that neurologists will have to deal with these comorbid conditions to a growing extent in the future. Read More

View Article and Full-Text PDF

CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease.

Nat Rev Neurol 2022 May 20. Epub 2022 May 20.

Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.

View Article and Full-Text PDF

Intranasal Oxytocin Attenuates Cognitive Impairment, β-Amyloid Burden and Tau Deposition in Female Rats with Alzheimer's Disease: Interplay of ERK1/2/GSK3β/Caspase-3.

Neurochem Res 2022 May 20. Epub 2022 May 20.

Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Pharos University in Alexandria, Alexandria, Egypt.

Oxytocin is a neuropeptide hormone that plays an important role in social bonding and behavior. Recent studies indicate that oxytocin could be involved in the regulation of neurological disorders. However, its role in modulating cognition in Alzheimer's disease (AD) has never been explored. Read More

View Article and Full-Text PDF

A History of Senile Plaques: From Alzheimer to Amyloid Imaging.

Thomas G Beach

J Neuropathol Exp Neurol 2022 May;81(6):387-413

From the Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona, USA.

Senile plaques have been studied in postmortem brains for more than 120 years and the resultant knowledge has not only helped us understand the etiology and pathogenesis of Alzheimer disease (AD), but has also pointed to possible modes of prevention and treatment. Within the last 15 years, it has become possible to image plaques in living subjects. This is arguably the single greatest advance in AD research since the identification of the Aβ peptide as the major plaque constituent. Read More

View Article and Full-Text PDF

Transauricular Vagal Nerve Stimulation at 40 Hz Inhibits Hippocampal P2X7R/NLRP3/Caspase-1 Signaling and Improves Spatial Learning and Memory in 6-Month-Old APP/PS1 Mice.

Neuromodulation 2022 May 17. Epub 2022 May 17.

Clinical Medical College of Acupuncture, Moxibustion, and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address:

Objectives: Transauricular vagal nerve stimulation (taVNS) at 40 Hz attenuates hippocampal amyloid load in 6-month-old amyloid precursor protein/presenilin 1 (APP/PS1) transgenic mice, but it is unclear whether 40-Hz taVNS can improve cognition in these mice. Moreover, the underlying mechanisms are still unclear.

Materials And Methods: 6-month-old C57BL/6 (wild type [WT]) and APP/PS1 mice were subjected to 40-Hz taVNS. Read More

View Article and Full-Text PDF

Pharmacogenetic studies in Alzheimer disease.

Neurologia (Engl Ed) 2022 May 1;37(4):287-303. Epub 2020 Jun 1.

Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana, Unidad Xochimilco, Coyoacán (México D.F.), Mexico. Electronic address:

Introduction: Alzheimer disease (AD) is the most common cause of dementia and is considered one of the main causes of disability and dependence affecting quality of life in elderly people and their families. Current pharmacological treatment includes acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine; however, only one-third of patients respond to treatment. Genetic factors have been shown to play a role in this inter-individual variability in drug response. Read More

View Article and Full-Text PDF

Z-scan optical method complements the Thioflavin T assay for investigation of anti-Alzheimer's impact of polyphenols.

Photodiagnosis Photodyn Ther 2022 May 17:102914. Epub 2022 May 17.

Biophotonics Lab, Faculty of Physics, Kharazmi University, Karaj 31979-37551, Iran; Applied Science Research Center, Kharazmi University, Karaj 31979-37551, Iran.

Polyphenols are tremendously effective in eliminating the amyloid-beta aggregations, the main hallmark of Alzheimer's disease. In recent years various nano drugs and biomaterials based on polyphenolic compounds have been synthetized to treat or prevent Alzheimer's disease, and the main in-vitro approach to investigate the anti-Alzheimer's properties of materials, is Thioflavin T assay. In spite of being very helpful, it has some drawbacks and cannot guarantee the accuracy of data, specifically in case of polyphenolic compounds; thus, rendering accurate results requires utilizing other assays along with Thioflavin T. Read More

View Article and Full-Text PDF

Alzheimer's Disease and Mild Cognitive Impairment Serious Games: A Systematic Analysis in Smartphone Application Markets.

Stud Health Technol Inform 2022 May;293:179-186

Department of Health Information Management, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.

Background: Patients with Alzheimer's disease and mild cognitive impairment can employ serious games to assess and improve their cognitive status.

Objectives: To determine the cognitive aspects of the MMSE and ACE-R tests that are supported by available games.

Methods: We searched cognitive games available in online application markets (Play Store, Galaxy Store, and App Store) using keywords: Alzheimer's Disease, dementia, and mild cognitive impairment. Read More

View Article and Full-Text PDF

Association of the top 20 Alzheimer's disease risk genes with [F]flortaucipir PET.

Alzheimers Dement (Amst) 2022 11;14(1):e12308. Epub 2022 May 11.

Department of Neurology Indiana University School of Medicine Indianapolis Indiana USA.

Introduction: We previously reported genetic associations of the top Alzheimer's disease (AD) risk alleles with amyloid deposition and neurodegeneration. Here, we report the association of these variants with [F]flortaucipir standardized uptake value ratio (SUVR).

Methods: We analyzed the [F]flortaucipir scans of 352 cognitively normal (CN), 160 mild cognitive impairment (MCI), and 54 dementia (DEM) participants from Alzheimer's Disease Neuroimaging Initiative (ADNI)2 and 3. Read More

View Article and Full-Text PDF

Lateralized and pathology in a case of Lewy body disease with corticobasal syndrome.

Alzheimers Dement (N Y) 2022 11;8(1):e12294. Epub 2022 May 11.

Department of Neurology University of Pennsylvania Philadelphia Pennsylvania USA.

Introduction: Lewy body diseases are pathologically characterized by α-synuclein pathology. Alzheimer's disease (AD) co-pathology can influence phenotypes. In vivo AD biomarkers can suggest the presence of this co-pathology in unusual cases, but pathological validation remains essential. Read More

View Article and Full-Text PDF

Communication about Alzheimer's disease and research among American Indians and Alaska Natives.

Alzheimers Dement (N Y) 2022 11;8(1):e12302. Epub 2022 May 11.

Institute for Research and Education to Advance Community Health Washington State University Seattle Washington USA.

Introduction: American Indian and Alaska Native (AI/AN) people infrequently participate in Alzheimer's disease (AD) research, despite the rapidly increasing population of AI/AN people aged 65 and older.

Methods: We surveyed 320 adults who identified as AI/AN at two Native-focused events and used ordinary least squares regression and logistic regression models to test associations between demographic factors and perceived risk of AD, knowledge about AD, and willingness to participate in research, along with preferred source of AD information.

Results: Willingness to participate in research was highest among those living in a city versus reservation and associated with perceived personal risk for AD. Read More

View Article and Full-Text PDF

Epidemiology of COVID-19 in Tehran, Iran: A Cohort Study of Clinical Profile, Risk Factors, and Outcomes.

Biomed Res Int 2022 10;2022:2350063. Epub 2022 May 10.

Students Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Background: The outbreak of coronavirus disease 2019 (COVID-19) dates back to December 2019 in China. Iran has been among the most prone countries to the virus. The aim of this study was to report demographics, clinical data, and their association with death and CFR. Read More

View Article and Full-Text PDF

Structural progression of Alzheimer's disease over decades: the MRI staging scheme.

Brain Commun 2022 28;4(3):fcac109. Epub 2022 Apr 28.

Univ. Bordeaux, CNRS, UMR5800, Bordeaux INP, LABRI, F-33400 Talence, France.

The chronological progression of brain atrophy over decades, from pre-symptomatic to dementia stages, has never been formally depicted in Alzheimer's disease. This is mainly due to the lack of cohorts with long enough MRI follow-ups in cognitively unimpaired young participants at baseline. To describe a spatiotemporal atrophy staging of Alzheimer's disease at the whole-brain level, we built extrapolated lifetime volumetric models of healthy and Alzheimer's disease brain structures by combining multiple large-scale databases ( = 3512 quality controlled MRI from 9 cohorts of subjects covering the entire lifespan, including 415 MRI from ADNI1, ADNI2 and AIBL for Alzheimer's disease patients). Read More

View Article and Full-Text PDF

Passion fruit seed extract protects beta-amyloid-induced neuronal cell death in a differentiated human neuroblastoma SH-SY5Y cell model.

Food Sci Nutr 2022 May 2;10(5):1461-1468. Epub 2022 Feb 2.

Research and Development Institute Health Science Research Center, Morinaga & Co., Ltd. Yokohama Japan.

Alzheimer's disease (AD) is a progressive neurodegenerative disease with accompanying perceptive disorder. We previously reported that decreasing levels of brain-derived neurotrophic factor (BDNF) promoted beta-amyloid (Aβ)-induced neuronal cell death in neuron-like differentiated SH-SY5Y (ndSH-SY5Y) human neuroblastoma cells in an AD mimic cell model. We investigated the neuroprotective effects of passion fruit seed extract (PFSE) and one of the main stilbene compounds, piceatannol, in an AD cell model using ndSH-SY5Y cells. Read More

View Article and Full-Text PDF

Fission Impossible: Stabilized miRNA-Based Analogs in Neurodegenerative Disease.

Walter J Lukiw

Front Neurosci 2022 3;16:875957. Epub 2022 May 3.

LSU Neuroscience Center, Louisiana State University Health Science Center, New Orleans, LA, United States.

View Article and Full-Text PDF

Integrating functional genomics with genetics to understand the biology of ALS and FTD.

Carlos Cruchaga

Med (N Y) 2022 Apr;3(4):226-227

Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA; NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA; The Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA. Electronic address:

Genetic variants in chromosome 19 are strongly associated with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Ma et al. and Brown et al. Read More

View Article and Full-Text PDF

Understanding the contributions of VPS35 and the retromer in neurodegenerative disease.

Neurobiol Dis 2022 May 16;170:105768. Epub 2022 May 16.

Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI 49503, USA. Electronic address:

Perturbations of the endolysosomal pathway have been suggested to play an important role in the pathogenesis of several neurodegenerative diseases, including Parkinson's disease (PD) and Alzheimer's disease (AD). Specifically, VPS35 and the retromer complex play an important role in the endolysosomal system and are implicated in the pathophysiology of these diseases. A single missense mutation in VPS35, Asp620Asn (D620N), is known to cause late-onset, autosomal dominant familial PD. Read More

View Article and Full-Text PDF

Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease.

Int J Psychophysiol 2022 May 16. Epub 2022 May 16.

Sapienza University of Rome, Department of Physiology and Pharmacology "V. Erspamer", Rome, Italy; San Raffaele of Cassino, Cassino, Italy.

Alzheimer's disease dementia (ADD) is the most diffuse neurodegenerative disorder belonging to mild cognitive impairment (MCI) and dementia in old persons. This disease is provoked by an abnormal accumulation of amyloid-beta and tauopathy proteins in the brain. Very recently, the first disease-modifying drug has been licensed with reserve (i. Read More

View Article and Full-Text PDF

Modulation of beta-amyloid aggregation using ascorbic acid.

Biochimie 2022 May 16. Epub 2022 May 16.

GNano - Nanomedicine and Nanotoxicology Group, Physics Institute of São Carlos, University of São Paulo, CP 369, 13560-970, São Carlos, SP, Brazil. Electronic address:

Studies have shown that the level of ascorbic acid (AA) is reduced in the brain of Alzheimer's disease (AD) patients. However, its effect on amyloid-β 1-42 (Aβ) aggregation has not yet been elucidated. Here we investigated for the first time the effect of AA on Aβ aggregation using fluorescence assay, circular dichroism, atomic force microscopy, isothermal titration calorimetry, ligand docking, and molecular dynamics. Read More

View Article and Full-Text PDF

Protective effects of phosphodiesterase 2 inhibitor against Aβ induced neuronal toxicity.

Neuropharmacology 2022 May 16;213:109128. Epub 2022 May 16.

Department of Anesthesiology, Rutgers New Jersey Medical School, The State University of New Jersey, Newark, NJ, 07101, USA. Electronic address:

Our previous study suggested that inhibition of Phosphodiesterase 2 ameliorates memory loss upon exposure to oxidative stress. While whether memory enhancing effects of PDE2 inhibition on Alzheimer's disease mouse model are involved in antioxidant defense and neuronal remodeling, are largely unexplored. The present study addressed whether and how PDE2 inhibitor Bay 60-7550 rescued Aβ oligomers (Aβo)-induced neuronal damage and memory impairment. Read More

View Article and Full-Text PDF

Decreased 5-HT binding in mild Alzheimer's disease - a PET study.

Synapse 2022 May 19. Epub 2022 May 19.

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm County, Stockholm, Sweden.

Introduction: Decreased 5-HT receptor binding has been associated with Alzheimer's disease (AD) and interpreted as a consequence of neuron loss. The purpose of the present study was to compare [ C]WAY100635 binding to the 5-HT receptor in hippocampus, entorhinal cortex, amygdala and pericalcarine cortex in mild AD patients and elderly controls.

Methods: AD patients (n = 7) and elderly control subjects (n = 8) were examined with positron emission tomography (PET) and [ C]WAY100635. Read More

View Article and Full-Text PDF

Modifiable Risk Factors for Alzheimer Disease and Related Dementias Among Adults Aged ≥45 Years - United States, 2019.

MMWR Morb Mortal Wkly Rep 2022 May 20;71(20):680-685. Epub 2022 May 20.

Alzheimer disease,* the most common cause of dementia, affects an estimated 6.5 million persons aged ≥65 years in the United States (1). A growing body of evidence has identified potential modifiable risk factors for Alzheimer disease and related dementias (ADRD) (1-3). Read More

View Article and Full-Text PDF

The new therapy for Alzheimer's disease: from a hope for a few to a false hope?

Aging Clin Exp Res 2022 May 19. Epub 2022 May 19.

IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia via Pilastroni 4, 25125, Brescia, Italy.

Since the late ninety, research on Alzheimer's disease has been focused on the search of drugs able to modify the disease course. Patients and caregivers waiting for news on this topic, received enthusiastically the advice of the approval of Aducanumab-anti-amyloid β monoclonal antibody-by the FDA, and that of its rejection by the EMA with even greater disappointment. To estimate the number of patients that we would be able to treat-hypothesizing a possible future approval by EMA- in the memory clinic of the IRCCS S. Read More

View Article and Full-Text PDF

The Current Landscape of Prevention Trials in Dementia.

Neurotherapeutics 2022 May 19. Epub 2022 May 19.

Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, USA.

As the prevalence of dementia and Alzheimer's disease (AD) increases worldwide, it is imperative to reflect on the major clinical trials in the prevention of dementia and the challenges that surround them. The pharmaceutical industry has focused on developing drugs that primarily affect the Aβ cascade and tau proteinopathy, while academics have focused on repurposed therapeutics and multi-domain interventions for prevention studies. This paper highlights significant primary, secondary, and tertiary prevention trials for dementia and AD, overall design, methods, and systematic issues to better understand the current landscape of prevention trials. Read More

View Article and Full-Text PDF

History in Perspective: The prime pathological players and role of phytochemicals in Alzheimer's disease.

IBRO Neurosci Rep 2022 Jun 28;12:377-389. Epub 2022 Apr 28.

Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi 110025, India.

Alzheimer's disease is a steadily progressive, irreversible neurological disorder that is most frequently categorized under the umbrella term "neurodegeneration". Several attempts are underway to clarify the pathogenic mechanisms, identify the aetiologies, and determine a pathway by which the therapeutic steps can be implemented. Oxidative stress is one of the pathogenic processes, which is commonly believed to be associated with neurodegenerative diseases. Read More

View Article and Full-Text PDF

Abnormal Dynamic Functional Networks in Subjective Cognitive Decline and Alzheimer's Disease.

Front Comput Neurosci 2022 2;16:885126. Epub 2022 May 2.

School of Life Science, Beijing Institute of Technology, Beijing, China.

Subjective cognitive decline (SCD) is considered to be the preclinical stage of Alzheimer's disease (AD) and has the potential for the early diagnosis and intervention of AD. It was implicated that CSF-tau, which increases very early in the disease process in AD, has a high sensitivity and specificity to differentiate AD from normal aging, and the highly connected brain regions behaved more tau burden in patients with AD. Thus, a highly connected state measured by dynamic functional connectivity may serve as the early changes of AD. Read More

View Article and Full-Text PDF

Dendrobium Nobile Lindl. Alkaloid Suppresses NLRP3-Mediated Pyroptosis to Alleviate LPS-Induced Neurotoxicity.

Front Pharmacol 2022 2;13:846541. Epub 2022 May 2.

School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Alzheimer's disease (AD) is a neurodegenerative disorder recognized as a global public health priority. Although available treatments temporarily relieve the symptoms, they could not prevent the progression of cognitive decline. Natural compounds have been rich sources for drug discovery. Read More

View Article and Full-Text PDF